Veritas In Silico (TSE:130A) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Veritas In Silico's annualized Gross Profit for the quarter that ended in Dec. 2024 was 円0.0 Mil. Veritas In Silico's average Total Assets over the quarter that ended in Dec. 2024 was 円2,321.0 Mil. Therefore, Veritas In Silico's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Veritas In Silico Gross-Profit-to-Asset % Historical Data

The historical data trend for Veritas In Silico's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico Gross-Profit-to-Asset % Chart

Veritas In Silico Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

3.38

10.66

22.15

9.97

Veritas In Silico Quarterly Data
	Dec21	Dec22	Sep23	Dec23	Mar24	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	19.46	6.32	13.94	-

Competitive Comparison of Veritas In Silico's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Veritas In Silico's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veritas In Silico's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veritas In Silico's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Veritas In Silico's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Veritas In Silico Gross-Profit-to-Asset % Calculation

Veritas In Silico's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	194.643	/	( (1655.531	+	2248.958)	/ 2 )
	=	194.643	/	1952.2445
	=	9.97 %

Veritas In Silico's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (2393.107	+	2248.958)	/ 2 )
	=	0	/	2321.0325
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Veritas In Silico Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Veritas In Silico Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031

Website

https://www.veritasinsilico.com

Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines